Creative Planning Increases Stock Holdings in Insmed, Inc. $INSM

Creative Planning raised its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 0.6% during the second quarter, Holdings Channel reports. The firm owned 72,176 shares of the biopharmaceutical company’s stock after buying an additional 432 shares during the quarter. Creative Planning’s holdings in Insmed were worth $7,264,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Mutual of America Capital Management LLC boosted its stake in shares of Insmed by 2.7% during the 1st quarter. Mutual of America Capital Management LLC now owns 79,141 shares of the biopharmaceutical company’s stock valued at $6,038,000 after purchasing an additional 2,093 shares in the last quarter. CWM LLC lifted its holdings in Insmed by 24.5% in the first quarter. CWM LLC now owns 2,052 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 404 shares during the period. Signaturefd LLC lifted its holdings in Insmed by 60.0% in the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 325 shares during the period. Teachers Retirement System of The State of Kentucky bought a new stake in Insmed during the 1st quarter valued at approximately $975,000. Finally, Allianz Asset Management GmbH boosted its position in Insmed by 4.9% during the 1st quarter. Allianz Asset Management GmbH now owns 75,284 shares of the biopharmaceutical company’s stock valued at $5,743,000 after acquiring an additional 3,534 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on INSM. UBS Group increased their target price on Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Bank of America upped their price target on Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Mizuho set a $196.00 price objective on Insmed in a research report on Wednesday, October 29th. Morgan Stanley boosted their target price on shares of Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Finally, JPMorgan Chase & Co. upped their target price on shares of Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 20th. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $173.29.

Insmed Stock Performance

Shares of Insmed stock opened at $203.56 on Thursday. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $205.11. The firm’s 50-day moving average is $165.61 and its 200 day moving average is $123.38. The stock has a market cap of $43.41 billion, a price-to-earnings ratio of -35.65 and a beta of 1.05. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The firm had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.27) earnings per share. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In related news, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the sale, the director directly owned 262,675 shares in the company, valued at approximately $38,190,318.25. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Alexander Smith sold 27,130 shares of Insmed stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the completion of the sale, the insider owned 54,902 shares of the company’s stock, valued at $10,089,889.56. This represents a 33.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 252,922 shares of company stock valued at $43,533,383 over the last ninety days. Corporate insiders own 3.00% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.